Bruce Bender
Concepts (395)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 90 | 2025 | 1930 | 11.080 |
Why?
| | Patient Compliance | 29 | 2024 | 618 | 4.420 |
Why?
| | Anti-Asthmatic Agents | 20 | 2022 | 275 | 4.300 |
Why?
| | Medication Adherence | 21 | 2024 | 522 | 3.270 |
Why?
| | Adrenal Cortex Hormones | 22 | 2022 | 507 | 2.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2023 | 1061 | 1.810 |
Why?
| | Telemedicine | 9 | 2024 | 929 | 1.680 |
Why?
| | Bronchodilator Agents | 8 | 2020 | 196 | 1.620 |
Why?
| | Food Hypersensitivity | 4 | 2020 | 190 | 1.600 |
Why?
| | Dermatitis, Atopic | 8 | 2018 | 336 | 1.420 |
Why?
| | Electronic Mail | 2 | 2021 | 65 | 1.280 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 97 | 1.180 |
Why?
| | Patient Education as Topic | 10 | 2021 | 786 | 1.100 |
Why?
| | Health Personnel | 4 | 2021 | 742 | 1.080 |
Why?
| | Self Care | 8 | 2021 | 389 | 1.070 |
Why?
| | Health Communication | 2 | 2018 | 49 | 1.060 |
Why?
| | Speech Recognition Software | 2 | 2018 | 11 | 1.020 |
Why?
| | Drug Monitoring | 5 | 2019 | 399 | 1.010 |
Why?
| | Humans | 131 | 2025 | 144748 | 0.970 |
Why?
| | Rhinitis, Allergic | 2 | 2018 | 44 | 0.960 |
Why?
| | Administration, Inhalation | 19 | 2023 | 597 | 0.900 |
Why?
| | Child | 54 | 2025 | 22928 | 0.860 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 45 | 0.840 |
Why?
| | Disease Management | 3 | 2018 | 647 | 0.820 |
Why?
| | Monitoring, Physiologic | 4 | 2019 | 290 | 0.810 |
Why?
| | Stress, Psychological | 5 | 2018 | 1144 | 0.810 |
Why?
| | Reminder Systems | 4 | 2024 | 175 | 0.800 |
Why?
| | Glucocorticoids | 4 | 2016 | 544 | 0.800 |
Why?
| | Metered Dose Inhalers | 5 | 2012 | 13 | 0.790 |
Why?
| | Hypersensitivity | 4 | 2024 | 259 | 0.770 |
Why?
| | Bullying | 2 | 2016 | 45 | 0.770 |
Why?
| | Cell Phone | 2 | 2021 | 82 | 0.730 |
Why?
| | Parents | 12 | 2022 | 1468 | 0.710 |
Why?
| | Communication | 3 | 2021 | 966 | 0.690 |
Why?
| | Personnel Management | 1 | 2021 | 18 | 0.680 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2005 | 28 | 0.660 |
Why?
| | Telecommunications | 2 | 2018 | 21 | 0.660 |
Why?
| | Text Messaging | 2 | 2020 | 183 | 0.660 |
Why?
| | Tobacco Products | 1 | 2022 | 91 | 0.660 |
Why?
| | Sleep Wake Disorders | 7 | 2016 | 319 | 0.650 |
Why?
| | Delivery of Health Care | 5 | 2023 | 954 | 0.640 |
Why?
| | Research Design | 4 | 2023 | 1126 | 0.610 |
Why?
| | Nurse-Patient Relations | 1 | 2020 | 68 | 0.600 |
Why?
| | Treatment Adherence and Compliance | 1 | 2019 | 27 | 0.590 |
Why?
| | Electronic Health Records | 3 | 2024 | 1177 | 0.590 |
Why?
| | Minority Groups | 5 | 2017 | 280 | 0.590 |
Why?
| | Self-Management | 2 | 2019 | 207 | 0.590 |
Why?
| | Biological Products | 1 | 2022 | 246 | 0.580 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2019 | 28 | 0.580 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 102 | 0.570 |
Why?
| | Organizational Culture | 1 | 2020 | 162 | 0.570 |
Why?
| | Prescription Drug Overuse | 1 | 2018 | 12 | 0.560 |
Why?
| | Workload | 1 | 2020 | 166 | 0.560 |
Why?
| | Motivation | 3 | 2020 | 621 | 0.550 |
Why?
| | Health Behavior | 3 | 2013 | 793 | 0.540 |
Why?
| | Behavioral Medicine | 1 | 2018 | 37 | 0.540 |
Why?
| | Quality of Life | 12 | 2020 | 3100 | 0.540 |
Why?
| | Urticaria | 1 | 2018 | 39 | 0.530 |
Why?
| | Health Promotion | 2 | 2014 | 766 | 0.520 |
Why?
| | Androstadienes | 3 | 2008 | 74 | 0.520 |
Why?
| | Tobacco Smoke Pollution | 2 | 2014 | 238 | 0.510 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 1133 | 0.510 |
Why?
| | Physician-Patient Relations | 5 | 2014 | 595 | 0.500 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 8 | 0.500 |
Why?
| | Spirometry | 5 | 2021 | 264 | 0.500 |
Why?
| | Laryngeal Diseases | 1 | 2016 | 32 | 0.490 |
Why?
| | Male | 57 | 2025 | 72211 | 0.480 |
Why?
| | Desensitization, Immunologic | 2 | 2018 | 95 | 0.470 |
Why?
| | Adolescent | 31 | 2024 | 22670 | 0.470 |
Why?
| | Science | 1 | 2016 | 54 | 0.460 |
Why?
| | Female | 59 | 2025 | 78074 | 0.460 |
Why?
| | Laryngoscopy | 1 | 2016 | 123 | 0.460 |
Why?
| | Adaptation, Psychological | 2 | 2018 | 689 | 0.450 |
Why?
| | Research Report | 1 | 2015 | 81 | 0.450 |
Why?
| | Pulmonary Medicine | 2 | 2016 | 83 | 0.440 |
Why?
| | Behavior Therapy | 1 | 2018 | 288 | 0.440 |
Why?
| | Primary Health Care | 5 | 2021 | 1797 | 0.430 |
Why?
| | Airway Obstruction | 1 | 2016 | 168 | 0.430 |
Why?
| | Telephone | 3 | 2020 | 181 | 0.430 |
Why?
| | Surveys and Questionnaires | 15 | 2021 | 6062 | 0.430 |
Why?
| | Anxiety | 5 | 2016 | 1098 | 0.420 |
Why?
| | Sublingual Immunotherapy | 1 | 2014 | 5 | 0.420 |
Why?
| | Therapeutics | 1 | 2014 | 14 | 0.410 |
Why?
| | Pruritus | 4 | 2010 | 64 | 0.410 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2014 | 21 | 0.410 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1048 | 0.410 |
Why?
| | Community-Institutional Relations | 1 | 2014 | 104 | 0.400 |
Why?
| | Quality of Health Care | 1 | 2018 | 650 | 0.400 |
Why?
| | Motivational Interviewing | 1 | 2014 | 118 | 0.370 |
Why?
| | Adult | 28 | 2023 | 40359 | 0.370 |
Why?
| | Nebulizers and Vaporizers | 5 | 2023 | 68 | 0.370 |
Why?
| | Family | 5 | 2022 | 687 | 0.360 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2014 | 184 | 0.360 |
Why?
| | Organizational Affiliation | 1 | 2011 | 5 | 0.350 |
Why?
| | Depression | 6 | 2018 | 1519 | 0.340 |
Why?
| | Budesonide | 5 | 2012 | 56 | 0.340 |
Why?
| | Behavioral Research | 1 | 2011 | 36 | 0.340 |
Why?
| | United States | 14 | 2025 | 15694 | 0.330 |
Why?
| | Child, Preschool | 14 | 2024 | 11876 | 0.330 |
Why?
| | Psychomotor Performance | 2 | 2004 | 325 | 0.330 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 328 | 0.320 |
Why?
| | Severity of Illness Index | 10 | 2019 | 2953 | 0.320 |
Why?
| | Reinforcement, Verbal | 1 | 2010 | 2 | 0.320 |
Why?
| | Socioeconomic Factors | 6 | 2022 | 1327 | 0.320 |
Why?
| | Art Therapy | 1 | 2010 | 21 | 0.310 |
Why?
| | Patient Participation | 2 | 2018 | 434 | 0.300 |
Why?
| | Histamine H1 Antagonists | 3 | 2005 | 27 | 0.300 |
Why?
| | Chronic Disease | 6 | 2018 | 1844 | 0.290 |
Why?
| | Pain | 1 | 2014 | 783 | 0.280 |
Why?
| | Evidence-Based Medicine | 3 | 2021 | 727 | 0.270 |
Why?
| | Curriculum | 1 | 2015 | 1064 | 0.270 |
Why?
| | Fluticasone | 4 | 2018 | 56 | 0.270 |
Why?
| | Focus Groups | 3 | 2011 | 579 | 0.270 |
Why?
| | Sex Chromosome Aberrations | 3 | 2002 | 72 | 0.270 |
Why?
| | Health Services Accessibility | 2 | 2015 | 1084 | 0.270 |
Why?
| | Cognition Disorders | 4 | 2014 | 533 | 0.260 |
Why?
| | Critical Care | 3 | 2021 | 691 | 0.260 |
Why?
| | Intensive Care Units | 1 | 2014 | 896 | 0.260 |
Why?
| | Technology | 2 | 2018 | 96 | 0.260 |
Why?
| | Middle Aged | 21 | 2020 | 35640 | 0.260 |
Why?
| | Health Literacy | 3 | 2021 | 179 | 0.250 |
Why?
| | Program Evaluation | 3 | 2025 | 951 | 0.250 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 349 | 0.240 |
Why?
| | Albuterol | 1 | 2006 | 76 | 0.240 |
Why?
| | Prednisone | 5 | 2022 | 232 | 0.240 |
Why?
| | Retrospective Studies | 7 | 2023 | 16942 | 0.240 |
Why?
| | Young Adult | 9 | 2022 | 14021 | 0.240 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 22 | 0.240 |
Why?
| | Environmental Exposure | 2 | 2018 | 589 | 0.230 |
Why?
| | Sleep | 3 | 2008 | 915 | 0.230 |
Why?
| | Loratadine | 2 | 2004 | 4 | 0.220 |
Why?
| | Guideline Adherence | 2 | 2021 | 576 | 0.220 |
Why?
| | Mood Disorders | 1 | 2006 | 140 | 0.220 |
Why?
| | Health Expenditures | 2 | 2016 | 195 | 0.220 |
Why?
| | Data Collection | 1 | 2007 | 658 | 0.210 |
Why?
| | Exercise | 1 | 2016 | 2197 | 0.210 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2016 | 1424 | 0.210 |
Why?
| | Diphenhydramine | 2 | 2003 | 38 | 0.210 |
Why?
| | Social Class | 2 | 2022 | 273 | 0.210 |
Why?
| | Qualitative Research | 2 | 2020 | 1605 | 0.210 |
Why?
| | Health Resources | 2 | 2016 | 128 | 0.200 |
Why?
| | Salmeterol Xinafoate | 2 | 2018 | 22 | 0.200 |
Why?
| | Sleep Stages | 1 | 2004 | 76 | 0.200 |
Why?
| | Colorado | 6 | 2020 | 4704 | 0.200 |
Why?
| | Nitric Oxide | 2 | 2019 | 900 | 0.200 |
Why?
| | Histamine H1 Antagonists, Non-Sedating | 1 | 2003 | 1 | 0.200 |
Why?
| | Research | 3 | 2016 | 439 | 0.200 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 25 | 0.200 |
Why?
| | Biomedical Research | 2 | 2021 | 706 | 0.190 |
Why?
| | Patient Dropouts | 1 | 2003 | 65 | 0.190 |
Why?
| | Risk-Taking | 1 | 2006 | 343 | 0.190 |
Why?
| | Overweight | 1 | 2007 | 603 | 0.190 |
Why?
| | Hospitalization | 6 | 2020 | 2342 | 0.190 |
Why?
| | Animals, Domestic | 1 | 2002 | 18 | 0.190 |
Why?
| | Caregivers | 2 | 2016 | 977 | 0.190 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2023 | 132 | 0.190 |
Why?
| | Age Factors | 6 | 2016 | 3336 | 0.180 |
Why?
| | Social Support | 4 | 2013 | 640 | 0.180 |
Why?
| | Hypnotics and Sedatives | 2 | 2003 | 218 | 0.170 |
Why?
| | Emotions | 2 | 2018 | 586 | 0.170 |
Why?
| | Income | 1 | 2022 | 198 | 0.170 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 629 | 0.170 |
Why?
| | Tobacco Use | 1 | 2022 | 66 | 0.170 |
Why?
| | Thoracic Diseases | 1 | 2021 | 12 | 0.170 |
Why?
| | Health Services Needs and Demand | 1 | 2023 | 283 | 0.170 |
Why?
| | Nedocromil | 3 | 2009 | 23 | 0.170 |
Why?
| | Disease Progression | 4 | 2024 | 2889 | 0.170 |
Why?
| | Adolescent Behavior | 1 | 2006 | 545 | 0.160 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 127 | 0.160 |
Why?
| | Smartphone | 2 | 2018 | 99 | 0.150 |
Why?
| | Models, Econometric | 1 | 2019 | 36 | 0.150 |
Why?
| | Behavior Control | 1 | 2019 | 13 | 0.150 |
Why?
| | Intelligence | 4 | 2007 | 135 | 0.150 |
Why?
| | Allergists | 1 | 2018 | 11 | 0.140 |
Why?
| | Telemetry | 1 | 2018 | 42 | 0.140 |
Why?
| | Patient-Centered Care | 2 | 2016 | 551 | 0.140 |
Why?
| | Receptor, ErbB-4 | 1 | 2018 | 19 | 0.140 |
Why?
| | Quality Improvement | 2 | 2019 | 1275 | 0.140 |
Why?
| | Exhalation | 1 | 2018 | 29 | 0.140 |
Why?
| | Prospective Studies | 7 | 2022 | 7956 | 0.140 |
Why?
| | Risk Factors | 8 | 2014 | 10739 | 0.140 |
Why?
| | Cloud Computing | 1 | 2017 | 7 | 0.140 |
Why?
| | Citalopram | 1 | 2018 | 34 | 0.140 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 48 | 0.130 |
Why?
| | Confidentiality | 1 | 2018 | 75 | 0.130 |
Why?
| | Health Plan Implementation | 1 | 2019 | 143 | 0.130 |
Why?
| | Respiratory System | 1 | 2019 | 159 | 0.130 |
Why?
| | Patient Advocacy | 2 | 2020 | 76 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2016 | 1673 | 0.130 |
Why?
| | Medical Informatics | 1 | 2018 | 99 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2018 | 229 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 182 | 0.130 |
Why?
| | Indians, North American | 2 | 2025 | 664 | 0.130 |
Why?
| | Dry Powder Inhalers | 1 | 2016 | 2 | 0.130 |
Why?
| | Sleep Medicine Specialty | 1 | 2016 | 12 | 0.130 |
Why?
| | Health Surveys | 2 | 2009 | 512 | 0.130 |
Why?
| | Biosensing Techniques | 1 | 2018 | 143 | 0.120 |
Why?
| | Larynx | 1 | 2016 | 64 | 0.120 |
Why?
| | Treatment Outcome | 9 | 2018 | 11498 | 0.120 |
Why?
| | Respiration | 1 | 2016 | 210 | 0.120 |
Why?
| | Practice Guidelines as Topic | 4 | 2021 | 1566 | 0.120 |
Why?
| | Time Factors | 2 | 2021 | 7074 | 0.110 |
Why?
| | Aged | 8 | 2019 | 25564 | 0.110 |
Why?
| | Suicidal Ideation | 2 | 2012 | 564 | 0.110 |
Why?
| | Health Services | 1 | 2016 | 116 | 0.110 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 77 | 0.110 |
Why?
| | Health Education | 1 | 2018 | 364 | 0.110 |
Why?
| | Problem Behavior | 1 | 2016 | 106 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2010 | 485 | 0.110 |
Why?
| | Self Efficacy | 1 | 2018 | 411 | 0.110 |
Why?
| | Air Pollution | 1 | 2018 | 332 | 0.110 |
Why?
| | Pilot Projects | 3 | 2013 | 1848 | 0.100 |
Why?
| | Mental Disorders | 2 | 2014 | 1167 | 0.100 |
Why?
| | Monosomy | 2 | 2004 | 12 | 0.100 |
Why?
| | Psychology | 1 | 2014 | 89 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 941 | 0.100 |
Why?
| | Chromosomes, Human, X | 2 | 2004 | 79 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 237 | 0.100 |
Why?
| | Cost Savings | 1 | 2013 | 86 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1678 | 0.100 |
Why?
| | Mobile Applications | 3 | 2024 | 194 | 0.100 |
Why?
| | Administration, Oral | 3 | 2018 | 847 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2014 | 5345 | 0.100 |
Why?
| | Turner Syndrome | 2 | 2004 | 65 | 0.100 |
Why?
| | Sex Factors | 3 | 2009 | 2101 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 3 | 2015 | 892 | 0.100 |
Why?
| | Ethanolamines | 1 | 2012 | 16 | 0.090 |
Why?
| | Lung Diseases | 2 | 2016 | 791 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2018 | 840 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 468 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2016 | 8103 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 202 | 0.090 |
Why?
| | Multimedia | 1 | 2011 | 13 | 0.090 |
Why?
| | Self Report | 2 | 2019 | 875 | 0.090 |
Why?
| | Equipment Design | 3 | 2020 | 535 | 0.090 |
Why?
| | Thinking | 1 | 2012 | 66 | 0.090 |
Why?
| | Amygdala | 2 | 2004 | 192 | 0.090 |
Why?
| | Emergency Service, Hospital | 2 | 2021 | 2290 | 0.080 |
Why?
| | Needs Assessment | 1 | 2013 | 393 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2190 | 0.080 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 59 | 0.080 |
Why?
| | Longitudinal Studies | 4 | 2007 | 3042 | 0.080 |
Why?
| | Odds Ratio | 3 | 2009 | 1061 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 663 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2012 | 1064 | 0.080 |
Why?
| | Forced Expiratory Volume | 3 | 2013 | 492 | 0.080 |
Why?
| | Patient Satisfaction | 3 | 2022 | 702 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 287 | 0.070 |
Why?
| | Interdisciplinary Communication | 1 | 2010 | 199 | 0.070 |
Why?
| | Comorbidity | 1 | 2014 | 1685 | 0.070 |
Why?
| | Program Development | 1 | 2011 | 372 | 0.070 |
Why?
| | Activity Cycles | 1 | 2008 | 4 | 0.070 |
Why?
| | Beclomethasone | 1 | 2008 | 9 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2011 | 459 | 0.070 |
Why?
| | Peer Group | 2 | 2013 | 253 | 0.070 |
Why?
| | Cohort Studies | 4 | 2013 | 5895 | 0.070 |
Why?
| | Infant | 3 | 2021 | 10095 | 0.070 |
Why?
| | Affect | 2 | 2014 | 319 | 0.070 |
Why?
| | Smoking | 2 | 2007 | 1583 | 0.070 |
Why?
| | Incidence | 2 | 2014 | 2864 | 0.070 |
Why?
| | Patients | 1 | 2009 | 180 | 0.070 |
Why?
| | Self Disclosure | 1 | 2007 | 66 | 0.070 |
Why?
| | Computers | 1 | 2007 | 68 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2905 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2008 | 90 | 0.060 |
Why?
| | Schools | 1 | 2010 | 460 | 0.060 |
Why?
| | Animals | 4 | 2018 | 38224 | 0.060 |
Why?
| | Social Isolation | 1 | 2007 | 71 | 0.060 |
Why?
| | Culture | 1 | 2008 | 130 | 0.060 |
Why?
| | Polysomnography | 1 | 2008 | 242 | 0.060 |
Why?
| | Child Behavior Disorders | 1 | 2007 | 144 | 0.060 |
Why?
| | Cocaine-Related Disorders | 1 | 2007 | 136 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2018 | 2022 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 442 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1372 | 0.060 |
Why?
| | Self-Assessment | 2 | 2003 | 75 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2016 | 6418 | 0.060 |
Why?
| | Attention | 2 | 2007 | 458 | 0.060 |
Why?
| | Attitude to Health | 1 | 2009 | 452 | 0.060 |
Why?
| | Monocytes | 1 | 2008 | 545 | 0.060 |
Why?
| | United States Indian Health Service | 1 | 2025 | 46 | 0.060 |
Why?
| | Health Status | 1 | 2010 | 832 | 0.050 |
Why?
| | Logistic Models | 3 | 2010 | 2111 | 0.050 |
Why?
| | Marijuana Abuse | 1 | 2007 | 232 | 0.050 |
Why?
| | Neuropsychological Tests | 2 | 2007 | 1118 | 0.050 |
Why?
| | Software | 1 | 2010 | 690 | 0.050 |
Why?
| | Societies, Medical | 2 | 2021 | 878 | 0.050 |
Why?
| | Health Care Sector | 1 | 2004 | 24 | 0.050 |
Why?
| | Parent-Child Relations | 2 | 2004 | 288 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2007 | 268 | 0.050 |
Why?
| | Drug Industry | 1 | 2004 | 48 | 0.050 |
Why?
| | Allergy and Immunology | 1 | 2024 | 43 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2004 | 93 | 0.050 |
Why?
| | Suicide, Attempted | 1 | 2007 | 405 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 792 | 0.050 |
Why?
| | Drug Costs | 1 | 2005 | 115 | 0.050 |
Why?
| | Drug Utilization | 2 | 2018 | 166 | 0.050 |
Why?
| | Poverty | 2 | 2020 | 531 | 0.050 |
Why?
| | Tacrolimus | 1 | 2004 | 200 | 0.050 |
Why?
| | Self Administration | 1 | 2003 | 131 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 105 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 125 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1993 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 721 | 0.050 |
Why?
| | Safety | 1 | 2005 | 359 | 0.050 |
Why?
| | Mass Screening | 2 | 2011 | 1338 | 0.050 |
Why?
| | Regression Analysis | 2 | 2016 | 1014 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2003 | 110 | 0.040 |
Why?
| | X Chromosome | 1 | 2002 | 69 | 0.040 |
Why?
| | Mosaicism | 1 | 2002 | 76 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2002 | 82 | 0.040 |
Why?
| | Aneuploidy | 1 | 2002 | 89 | 0.040 |
Why?
| | Smoking Prevention | 1 | 2002 | 170 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2005 | 433 | 0.040 |
Why?
| | Italy | 1 | 2021 | 114 | 0.040 |
Why?
| | Hippocampus | 2 | 2004 | 960 | 0.040 |
Why?
| | Social Behavior | 1 | 2003 | 294 | 0.040 |
Why?
| | Health Care Costs | 1 | 2004 | 421 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2002 | 195 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2007 | 856 | 0.040 |
Why?
| | Cost of Illness | 1 | 2003 | 318 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2102 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2019 | 24 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 74 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 860 | 0.040 |
Why?
| | Patient Selection | 1 | 2003 | 699 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2019 | 3644 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2002 | 294 | 0.040 |
Why?
| | Body Mass Index | 1 | 2007 | 2453 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 127 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 201 | 0.030 |
Why?
| | Artificial Intelligence | 1 | 2022 | 366 | 0.030 |
Why?
| | Placebos | 1 | 2018 | 195 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2019 | 124 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 321 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 777 | 0.030 |
Why?
| | Organizational Policy | 1 | 2016 | 78 | 0.030 |
Why?
| | Insurance Claim Review | 1 | 2016 | 86 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 99 | 0.030 |
Why?
| | Intelligence Tests | 2 | 2007 | 63 | 0.030 |
Why?
| | Education | 1 | 2015 | 107 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2849 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1271 | 0.030 |
Why?
| | Vital Capacity | 2 | 2009 | 312 | 0.030 |
Why?
| | Wounds and Injuries | 1 | 2002 | 955 | 0.030 |
Why?
| | MP3-Player | 1 | 2013 | 2 | 0.030 |
Why?
| | Phenotype | 1 | 2002 | 3236 | 0.030 |
Why?
| | Philadelphia | 1 | 2013 | 55 | 0.030 |
Why?
| | United Kingdom | 1 | 2014 | 338 | 0.020 |
Why?
| | Lung | 2 | 2023 | 4131 | 0.020 |
Why?
| | Demography | 2 | 2004 | 297 | 0.020 |
Why?
| | Formoterol Fumarate | 1 | 2012 | 7 | 0.020 |
Why?
| | Memory | 1 | 2014 | 268 | 0.020 |
Why?
| | Medical Records | 2 | 2003 | 185 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2011 | 97 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 568 | 0.020 |
Why?
| | Psychometrics | 2 | 2007 | 746 | 0.020 |
Why?
| | Models, Organizational | 1 | 2011 | 144 | 0.020 |
Why?
| | Urban Population | 1 | 2013 | 493 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1222 | 0.020 |
Why?
| | Models, Psychological | 1 | 2011 | 313 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2008 | 3403 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2061 | 0.020 |
Why?
| | Pregnancy | 1 | 2002 | 7211 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2015 | 689 | 0.020 |
Why?
| | Emergencies | 1 | 2009 | 181 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 434 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 208 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 62 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2007 | 123 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 3 | 2004 | 3834 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.010 |
Why?
| | Models, Statistical | 1 | 2009 | 689 | 0.010 |
Why?
| | Educational Status | 1 | 2007 | 466 | 0.010 |
Why?
| | Child Behavior | 1 | 2007 | 253 | 0.010 |
Why?
| | Administration, Topical | 1 | 2004 | 154 | 0.010 |
Why?
| | Internet | 1 | 2009 | 701 | 0.010 |
Why?
| | Language Disorders | 1 | 2003 | 31 | 0.010 |
Why?
| | Cross-Sectional Studies | 2 | 2007 | 5797 | 0.010 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2003 | 28 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2002 | 38 | 0.010 |
Why?
| | Dogs | 1 | 2003 | 431 | 0.010 |
Why?
| | Karyotyping | 1 | 2002 | 106 | 0.010 |
Why?
| | Appointments and Schedules | 1 | 2002 | 102 | 0.010 |
Why?
| | Disclosure | 1 | 2002 | 86 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 2003 | 323 | 0.010 |
Why?
| | Age of Onset | 1 | 2003 | 559 | 0.010 |
Why?
| | Motor Skills | 1 | 2002 | 106 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1315 | 0.010 |
Why?
| | Outpatients | 1 | 2004 | 426 | 0.010 |
Why?
| | Forecasting | 1 | 2002 | 386 | 0.010 |
Why?
| | Growth | 1 | 2000 | 52 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2002 | 270 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1514 | 0.010 |
Why?
| | Skin | 1 | 2004 | 774 | 0.010 |
Why?
|
|
Bender's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|